Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
GLP-1 receptor agonists were developed primarily to improve glucose control and, in many cases, support weight loss
Exclusivity is a multi-layered construct: CoM patents, secondary thickets, and FDA regulatory exclusivities (NCE, ODE, pediatric) all contribute, and their interactions determine the total exclusivity duration
Stop immediately and contact your doctor if: Severe neck swelling or a palpable thyroid mass develops Symptoms of thyrotoxicosis appear: rapid heartbeat, severe anxiety, excessive sweating, tremor, sudden unexplained weight loss Severe pancreatitis symptoms: intense upper abdominal pain radiating to the back with nausea and vomiting You discover you are pregnant Discuss with your endocrinologist if: TSH levels become unstable despite levothyroxine adjustments New thyroid nodules appear on follow-up ultrasound Hair loss is severe and persistent despite adequate nutrient levels Fatigue worsens despite thyroid levels appearing normal Autoimmune flare frequency appears to increase You reach your target weight and want to explore discontinuation For patients who achieve their weight loss goals and want to stop GLP-1 therapy, tapering is recommended over abrupt discontinuation
The chocolate flavor offers an enjoyable way to support your muscle preservation goals
effects probably related to its anti-diabetic and weight-lowering properties
In its standing guidance on unapproved GLP-1 drugs, the US FDA warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide or retatrutide that are falsely labeled for research purposes or not for human consumption. The agency was specific that these products have been sold directly to consumers for human use with dosing instructions, which is to say the FDA understands perfectly well that the research only label is a fig leaf and has said so
